Corcept Stock Plummets as Teva Wins Patent Ruling Over Generic Korlym

Corcept Therapeutics (CORT) shares plunged following a court ruling in favor of Teva Pharmaceuticals regarding the drug Korlym. The court rejected Corcept's claims that Teva’s generic version of the Cushing's syndrome treatment infringed on its dosing patents. This legal victory allows Teva to proceed with its generic alternative, effectively ending Corcept's market exclusivity for the drug. The judge determined that Teva's labeling would not induce healthcare providers to infringe on Corcept’s patented methods involving mifepristone. For Corcept, the loss of patent protection represents a significant revenue risk as generic competition enters the market. Conversely, the ruling strengthens Teva's generic portfolio and is expected to provide a more affordable option for patients.